Back to School: How biopharma can reboot drug development. Access exclusive analysis here
OSIP subsidiary Prosidion Ltd. (Oxford, U.K.) acquired from Probiodrug a dipeptidyl peptidase-4 (DPP-4) program for metabolic indications
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury